EMA Authorised: Altuvoct (Efanesoctocog alfa) — Swedish Orphan Biovitrum AB (publ)

View source ↗

Summary

EMA has authorised Altuvoct (efanesoctocog alfa) for Hemophilia A, marking an orphan medicine approval by Swedish Orphan Biovitrum AB (publ).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Altuvoct (efanesoctocog alfa)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Swedish Orphan Biovitrum AB (publ). Decision date: 03/07/2026. Orphan medicine